Binds A Receptor (e.g., Transferrin Receptor, Fc Receptor, Dihydropyridine Receptor, Il-2 Receptor, Etc.) Patents (Class 435/334)
  • Patent number: 10066014
    Abstract: An isolated antibody comprising an antigen recognition domain which specifically binds CD84 and (i) down regulates the anti-apoptotic activity of stromal cells on chronic lymphocytic leukemia (CLL) cells; and/or (ii) induces mobilization of CLL cells from the bone marrow. Also provided are antibodies comprising antigen recognition domains comprising complementarity determining regions as indicated and uses thereof.
    Type: Grant
    Filed: February 5, 2015
    Date of Patent: September 4, 2018
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Idit Shachar, Inbal Binsky, Ayelet Marom
  • Publication number: 20150147278
    Abstract: The present invention provides a prophylactic or therapeutic agent for various malignant tumors, including currently intractable solid tumors, which contains a novel antibody having the ability to bind to human LAT1/CD98 and inducing antibody-dependent cellular cytotoxicity specifically against cancer cells as an active ingredient.
    Type: Application
    Filed: December 5, 2014
    Publication date: May 28, 2015
    Applicants: Kinki University, Link Genomics, Inc.
    Inventors: Takashi Masuko, Shinichiro Niwa, Hidemi Hayashi, Dai Ogura, Takayuki Shindou
  • Publication number: 20150147274
    Abstract: Antibodies which are antagonists of the human HGF receptor (MET), wherein the antibodies specifically bind to amino acid residues 568-741 of human MET (SEQ ID No: 1) with high affinity.
    Type: Application
    Filed: November 30, 2012
    Publication date: May 28, 2015
    Inventors: Danielle Marie Di Cara, John McCafferty, Ermanno Gherardi, Anthony Richard Pope
  • Publication number: 20150147344
    Abstract: The invention relates to BTLA antibodies that block BTLA-HVEM interaction and uses thereof.
    Type: Application
    Filed: November 21, 2014
    Publication date: May 28, 2015
    Inventor: Daniel Olive
  • Patent number: 9040670
    Abstract: Monoclonal antibodies (mAbs) having thyroid stimulating activity (TSAb), especially full or considerably agonistic activity, or thyroid blocking activity (TBAb), which are obtainable by genetic immunization of mice, or fragments (F(ab?)2, Fab or Fv) or humanized forms of such monoclonal antibodies or single chain forms (SCA; scFv) of such fragments, which antibodies, or their fragments, compete with bovine TSH for epitopes of the human TSHr, compete with autoantibodies from sera from Graves' patients as well as with autoantibodies from sera from patients harboring blocking autoantibodies for epitopes of the human TSHr, bind to conformational epitopes of the human TSHr located in the first 281 amino acids of the human TSHr, and usually also bind to TSFR receptors (TSHr) from different animals. Various uses of such antibodies, or of peptides corresponding to variable regions of such antibodies, are also described and claimed.
    Type: Grant
    Filed: July 12, 2011
    Date of Patent: May 26, 2015
    Assignee: B.R.A.H.M.S GMBH
    Inventors: Andreas Bergmann, Nils G. Morgenthaler, Gilbert Vassart, Sabine Costagliola
  • Publication number: 20150125470
    Abstract: Provided is a pharmaceutical composition for the treatment and/or prophylaxis of abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.
    Type: Application
    Filed: March 29, 2013
    Publication date: May 7, 2015
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Yoshiharu Hiruma, Jun Hasegawa
  • Patent number: 9023996
    Abstract: The present invention relates to anti-FLT3 antibodies with a modified Fc region comprising the amino acid substitutions 239D and 332E to enhance antibody-dependent cell cytotoxicity (ADCC) of these antibodies. The invention further relates to pharmaceutical compositions containing these antibodies, nucleic acids encoding these antibodies as well as methods of using such antibodies.
    Type: Grant
    Filed: December 23, 2010
    Date of Patent: May 5, 2015
    Assignee: Synimmune GmbH
    Inventors: Ludger Grosse-Hovest, Hans-Joerg Buehring, Martin Hofmann, Steffen Aulwurm, Grundram Jung
  • Patent number: 9005963
    Abstract: The present invention relates to amino acid sequences that are directed against (as defined herein) human cellular receptors for viruses and/or bacteria such as e.g. NANOBODIES specifically recognizing hCD4, hCXCR4, hCCR5, hTLR4, human alphaV integrin, human beta3 integrin, human beta1 integrin, human alpha2 integrin, hCD81, hSR-BI, hClaudin-1, hClaudin-6 and hClaudin-9, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The amino acid sequences may be used to prevent human cell entry of HIV, HCV, adenoviruses, hantavirus, herpesvirus, echo-virus 1 and others.
    Type: Grant
    Filed: October 14, 2009
    Date of Patent: April 14, 2015
    Assignee: Ablynx N.V.
    Inventors: Christophe Blanchetot, Martine Smit, Regorius Leurs, Sven Jähnichen, Dominique Schols, Michael John Scott Saunders, Johannes Joseph Wilhelmus De Haard, Peter Vanlandschoot, Peter Verheesen
  • Patent number: 8999708
    Abstract: The present invention relates to antibodies that specifically bind to IL12R?1, the non-signal transducing chain of both the heterodimeric IL12 and IL23 receptors. The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFN? production of blood cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFN? production, IL12 and/IL23 signaling, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.
    Type: Grant
    Filed: October 3, 2013
    Date of Patent: April 7, 2015
    Assignee: Novartis AG
    Inventors: Jose M. Carballido Herrera, Stefan Hartle, Christoph Heusser, Ingo Klagge, Andrea Polzer, Christoph Schwaerzler, Gabriela Wochnik-Veltrup
  • Patent number: 8986954
    Abstract: A Nav1.7 binding entity that after binding functionally modifies the activity of the ion channel, in particular an anti-Nav1.7 antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.
    Type: Grant
    Filed: May 23, 2014
    Date of Patent: March 24, 2015
    Assignee: UCB Pharma S.A.
    Inventors: Helene Margaret Finney, Terence Seward Baker, Alastair David Griffiths Lawson, Karen Margrete Miller, Marc Roger de Ryck, Christian Gilbert J. Wolff
  • Publication number: 20150079104
    Abstract: The invention provides methods for inhibiting the interaction of endosialin with endosialin ligands. The inhibition is effectuated on the genetic level, by inhibiting endosialin gene expression, and on the protein level, by blocking the interaction of cell-surface expressed endosialin with ligands such as fibronectin and collagen. The invention provides methods for identifying inhibitors of the interaction of endosialin with endosialin ligands. Also provided are methods for inhibiting angiogenesis and neovascularization in vivo and in vitro.
    Type: Application
    Filed: October 8, 2014
    Publication date: March 19, 2015
    Inventors: Yuhong Zhou, Brian Tomkowicz, Luigi Grasso, Nicholas C. Nicolaides, Philip M. Sass
  • Publication number: 20150078996
    Abstract: The present invention relates to mammalian antibodies, designated 12B1 and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), preferably human IGF-IR. Also included are chimeric, bispecific, derivatized, single chain antibodies derived from the antibodies disclosed herein. Nucleic acid molecules encoding the mammalian antibodies as well as methods of use thereof are also disclosed. Also included are pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for treatment and diagnosis of pathological hyperproliferative oncogenic disorders associated with expression of IGf-1R.
    Type: Application
    Filed: September 19, 2014
    Publication date: March 19, 2015
    Inventors: Liliane Goetsch, David Brooks, Michael Chastain, Zhi-Qiang Zhang, Nathalie Corvaia
  • Publication number: 20150080556
    Abstract: The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: November 24, 2014
    Publication date: March 19, 2015
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Georg FERTIG, Alexander FIDLER, Klaus KALUZA, Marlene THOMAS, Carola RIES, Stefan SEEBER
  • Patent number: 8981072
    Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: March 17, 2015
    Assignees: Bristol-Myers Squibb Company, Domantis Limited
    Inventors: Steven G. Nadler, James K. Tamura, Laura Price, Robert P. Rehfuss, Suzanne J. Suchard, Anish Suri, James William Bryson, Aaron Yamniuk, Steven Grant, Olga Ignatovich, Philip Drew
  • Patent number: 8975384
    Abstract: The present invention provides a tag peptide comprising an amino acid sequence represented by the following formula (I): X1-Tyr-X2-Gly-Gln-X3??(I) (wherein X1, X2 and X3 are the same or different and each represent any amino acid residue) and an antibody against the tag peptide. By combined use of the tag peptide and antibody of the present invention, a system that enables proteins expressed from cloned genes to be highly purified in an inexpensive and easy manner can be established.
    Type: Grant
    Filed: December 18, 2008
    Date of Patent: March 10, 2015
    Assignee: Osaka University
    Inventor: Junichi Takagi
  • Patent number: 8962341
    Abstract: An assay system designed to detect a protein biomarker in urine that is diagnostic for interstitial cystitis (IC). The presence of a 9 amino acid glycopeptide, antiproliferative factor (APF), in urine is unique to patients with IC. Urine samples from patients who exhibit symptoms consistent with IC are added to the assay system. Binding of APF to the cytoskeletal associated protein 4 (CKAP4) is positive for the presence of APF in urine and diagnostic for IC. The diagnostic system is a significant and surprising advance in diagnosis of IC and has commercial applications relevant to women and men who suffer from symptoms consistent with IC.
    Type: Grant
    Filed: December 10, 2009
    Date of Patent: February 24, 2015
    Assignees: The Commonwealth Medical College, University of Florida Research Foundation, Inc.
    Inventors: David Alan Zacharias, Sonia Lobo Planey
  • Publication number: 20150050278
    Abstract: Fc domains and CH3 domains are disclosed that bind the neonatal Fc (FcRn) receptor and are at least 99% monomeric. Monomeric Fc domain molecules and CH3 domain molecules are disclosed herein that include a monomeric Fc domain or a monomeric CH3 domain and an effector molecule. In some embodiments, the monomeric Fc or monomeric CH3 domain include amino acid substitutions and/or CDR insertions in the beta strands such that they specifically bind an antigen. Methods for using these monomeric Fc domains, monomeric CH3 domains, monomeric Fc domain molecules and CH3 domain molecules are also provided.
    Type: Application
    Filed: March 14, 2013
    Publication date: February 19, 2015
    Inventors: Dimiter S. Dimitrov, Tianlei Ying
  • Publication number: 20150050270
    Abstract: The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg9-Bradykinin and des-Arg10-Kallidin-like peptide.
    Type: Application
    Filed: March 15, 2013
    Publication date: February 19, 2015
    Applicant: SANOFI
    Inventors: Han Li, Dorothea Kominos, Jie Zhang, Alla Pritzker, Matthew Davison, Nicolas Baurin, Govindan Subramanian, Xin Chen
  • Patent number: 8956852
    Abstract: The invention discloses novel methods of producing hydrocarbons through heterotrophic cultivation of Botryococcus braunii. Also provided are novel hydrocarbon compositions. A preferred species for engineering is the microalgae species Botryococcus braunii. Additional methods of cultivation include providing certain nutrient sources.
    Type: Grant
    Filed: August 23, 2012
    Date of Patent: February 17, 2015
    Assignee: Solazyme, Inc.
    Inventors: Chung-Soon Im, Diana Vincent, Rika Regentin, Anna Coragliotti
  • Patent number: 8956609
    Abstract: The present application is directed to the identification of mutations and/or polymorphisms in the Dual Endothelin-1/Angiotensin II Receptor (Dear) that indicate susceptibility to, or show current affliction with, hypertension. Additionally, the present invention discloses methods for the modulation of angiogenesis via the regulation of Dear.
    Type: Grant
    Filed: January 27, 2014
    Date of Patent: February 17, 2015
    Assignee: Trustees of Boston University
    Inventors: Victoria L. M. Herrera, Nelson Ruiz-Opazo
  • Patent number: 8945547
    Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor and inhibits tumor growth. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: February 3, 2015
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Timothy Charles Hoey, Maureen Fitch Bruhns, Fumiko Takada Axelrod
  • Patent number: 8945873
    Abstract: The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: February 3, 2015
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Timothy Charles Hoey, Edward Thein Htun van der Horst, Aaron Ken Sato, Yuan Ching Liu, Maureen Fitch Bruhns, John A. Lewicki
  • Patent number: 8945874
    Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor and inhibits tumor growth. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: February 3, 2015
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Timothy Charles Hoey, Maureen Fitch Bruhns, Fumiko Takada Axelrod
  • Patent number: 8945870
    Abstract: An object of the present invention is to provide a monoclonal antibody which is useful for treating or diagnosing a disease relating to system ASC amino acid transporter 2 (hereinafter, referred to as “ASCT2”) or a method using the antibody. The present invention provides a monoclonal antibody which specifically recognizes a native three-dimensional structure of an extracellular region of ASCT2 and binds to the extracellular region, or an antibody fragment thereof; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof, and a diagnostic agent using the antibody or the antibody fragment thereof.
    Type: Grant
    Filed: August 13, 2012
    Date of Patent: February 3, 2015
    Assignee: Kyowa Hakko Kirin Co., Ltd
    Inventors: Norihiko Shiraishi, Akiko Furuya, Hiroe Toki, Hiroshi Ando, Masayo Suzuki, Tsuguo Kubota
  • Publication number: 20150004177
    Abstract: Isolated monoclonal antibodies which bind to human CD32b and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: June 27, 2014
    Publication date: January 1, 2015
    Inventors: Edward Norbert VAN DEN BRINK, Paul PARREN, Jan VAN DE WINKEL, Aran Frank LABRIJN, Frank Everhardus Martinus REBERS, Esther Cornelia Wilhelmina BREIJ
  • Patent number: 8921106
    Abstract: Isolated antibodies that specifically binds to an extracellular conserved ligand binding region of a human Notch receptor and inhibits growth of a tumor are described. Also described are methods of treating cancer, the method comprising administering an anti-Notch antibody in an amount effective to inhibit tumor growth.
    Type: Grant
    Filed: May 9, 2013
    Date of Patent: December 30, 2014
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Aaron Ken Sato, Maureen Fitch-Bruhns
  • Publication number: 20140377284
    Abstract: The invention provides antibodies that specifically bind to human CD134. Anti-human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 T lymphocytes (Tregs). Humanized anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment.
    Type: Application
    Filed: March 20, 2014
    Publication date: December 25, 2014
    Applicants: JANSSEN PHARMACEUTICALS, INC., BIOCEROX PRODUCTS B.V.
    Inventors: Petrus Johannes SIMONS, Louis BOON, Jinquan LUO, Randall BREZSKI, Monica GOLDBERG
  • Publication number: 20140377270
    Abstract: The present invention is directed to optimized anti-CD3 variable sequences for use in a variety of bispecific formats, including those that utilize scFv components. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide.
    Type: Application
    Filed: March 12, 2014
    Publication date: December 25, 2014
    Inventors: Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
  • Publication number: 20140370548
    Abstract: Recombinant materials and methods for producing antibodies that specifically bind heregulin-coupled HER3, at a site distinct from the heregulin binding site, are described. These antibodies are particularly useful in treating cancer that expresses HER3.
    Type: Application
    Filed: September 2, 2014
    Publication date: December 18, 2014
    Inventors: Bruce KEYT, Lawrence M. KAUVAR, Ellen J. COLLARINI, Orit FOORD, Gizette SPERINDE, Marjan FATHOLAHI, Hung NGUYEN
  • Publication number: 20140363429
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof that bind the extracellular domain of the HER3 receptor and inhibit various HER3 receptor related functions via ligand-dependent and/or ligand-independent mechanisms. Also provided are compositions with increased half-life. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER3 mediated signal transduction.
    Type: Application
    Filed: November 20, 2012
    Publication date: December 11, 2014
    Applicant: MedImmune LLC
    Inventors: Partha S. Chowdhury, David Tice, Zhan Xiao, Philipp Steiner, Krista Kinneer, Marlon Rebelatto
  • Publication number: 20140335102
    Abstract: Methods are disclosed for increasing the binding affinity of binding proteins using in silico affinity maturation.
    Type: Application
    Filed: December 18, 2012
    Publication date: November 13, 2014
    Applicant: Sanofi
    Inventors: Michael Oberlin, Romano Kroemer, Vincent Mikol, Hervé Minoux, Nicolas Baurin
  • Publication number: 20140336363
    Abstract: The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: December 12, 2012
    Publication date: November 13, 2014
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Georg Fertig, Alexander Fidler, Klaus Kaluza, Carola Ries, Stefan Seeber, Marlene Thomas
  • Patent number: 8883992
    Abstract: Isolated nucleic acids encoding anti-CD19 mouse monoclonal antibodies are described herein. Also described are expression vectors, host cells and a method of producing anti-CD19 antibodies.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: November 11, 2014
    Assignee: Medimmune, LLC
    Inventors: Melissa Damschroder, Peter Kiener, Herren Wu, William Dall'Acqua, Ronald Herbst, Anthony Coyle
  • Patent number: 8877189
    Abstract: Binding members, especially antibody molecules, for interleukin (IL)-4 receptor alpha (IL-4R?), and their therapeutic use e.g. in treating or preventing disorders associated with IL-4R?, IL-4 and/or IL-13, examples of which are asthma and COPD.
    Type: Grant
    Filed: June 6, 2013
    Date of Patent: November 4, 2014
    Assignee: MedImmune Limited
    Inventors: Per-Olof Fredrik Eriksson, Karin Von Wachenfeldt, Suzanne Cohen, Claire Louise Dobson, Deborah Louise Lane
  • Publication number: 20140322233
    Abstract: Antibodies and antigen-binding fragments of antibodies that bind GCC are disclosed. The antibodies bind an extracellular domain of GCC and can be internalized. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.
    Type: Application
    Filed: June 2, 2014
    Publication date: October 30, 2014
    Inventors: Samuel S. Nam, Edward A. Greenfield, John S. Babcook, Theresa O'Keefe, Shixin Qin
  • Publication number: 20140308206
    Abstract: The disclosure relates to antibodies that bind FcRn and methods of using these antibodies.
    Type: Application
    Filed: June 1, 2012
    Publication date: October 16, 2014
    Applicant: DYAX CORP.
    Inventors: Daniel J. Sexton, Christopher Tenhoor, Malini Viswanathan
  • Publication number: 20140301946
    Abstract: The present invention relates to anti-FGFR2 and FGFR4 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Application
    Filed: March 11, 2014
    Publication date: October 9, 2014
    Applicant: NOVARTIS AG
    Inventors: David Bryant BATT, Seth Alexander Ettenberg, Nicole Haubst, Tiancen Hu, David Jenkins, Engin Toksoz, Konstantin Petropoulos, Matthew John Meyer
  • Publication number: 20140288275
    Abstract: The invention provides novel heterodimeric proteins including heterodimeric antibodies.
    Type: Application
    Filed: March 11, 2014
    Publication date: September 25, 2014
    Applicant: Xencor, Inc.
    Inventors: Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
  • Publication number: 20140275492
    Abstract: The present invention provides for methods of producing human monoclonal antibodies against a wide variety of antigens including bacterial and viral antigens, as well as tumor antigens, and various autoantigens. Also provided are the antibodies themselves, nucleic acids encoding such antibodies, cells producing such antibodies, and methods of using such antibodies for diagnostic assays and passive immunity against disease states such as infection and cancer.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Applicant: MUSC Foundation for Research Development
    Inventors: Natalie SUTKOWSKI, Semyon Rubinchik
  • Publication number: 20140275487
    Abstract: The present invention relates to the field of G protein coupled receptor (GPCR) structural biology and signaling. In particular, the present invention relates to binding domains directed against and/or specifically binding to GPCR:G protein complexes. Also provided are nucleic acid sequences encoding such binding domains and cells expressing or capable of expressing such binding domains. The binding domains of the present invention can be used as universal tools for the structural and functional characterization of G-protein coupled receptors in complex with downstream heterotrimeric G proteins and bound to various natural or synthetic ligands, for investigating the dynamic features of G protein activation, as well as for screening and drug discovery efforts that make use of GPCR:G protein complexes.
    Type: Application
    Filed: June 21, 2012
    Publication date: September 18, 2014
    Inventors: Jan Steyaert, Els Pardon, Toon Laeremans, Brian Kobilka, Søren Rasmussen, Sébastien Granier, Roger K. Sunahara
  • Patent number: 8835119
    Abstract: The invention refers to an in vitro method of functionally determining at physiological conditions deficiencies in the lectin pathway of the complement system, the method comprising the steps of (a) providing a sample of mammalian blood, serum, plasma or another body fluid; (b) preventing in the sample the activation of the classical pathway by contacting the sample with an inhibitor of a molecule of the C1 complex of the complement system; (e) preventing in the sample the activation of the alternative pathway; (d) activating the lectin pathway in the sample; and (e) determining in the sample any activation of the autologous C5b-9 complex.
    Type: Grant
    Filed: July 11, 2003
    Date of Patent: September 16, 2014
    Assignee: Euro Diagnostica AB
    Inventors: Johanna Roos, Mohamed R. Daha, Lee H. Bouwman, Cornelis Erik Hack
  • Publication number: 20140255995
    Abstract: A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a KD of about 500 pM or less and blocks IL-6 activity with an IC50 of 200 pM or less, is provided. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 11, 2014
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Eric Smith, Kevin J. Pobursky, Nicholas J. Papadopoulos, James P. Fandl, Gang Chen, Margaret Karow
  • Publication number: 20140248282
    Abstract: As a result of producing anti-DDR1 antibodies and conducting extensive studies on the antitumor activity thereof, antibodies that bind to the stalk domain in the amino acid sequence of human DDR1 were found to have a potent activity even when used alone compared to antibodies that bind to other domains. It was also found that the antibodies have one or more activities selected from the group consisting of: (i) an activity to suppress cell proliferation, (ii) an activity to inhibit cell migration, (iii) an activity to inhibit phosphorylation of DDR1 in cells, (iv) an activity to be taken up into cells, (v) an activity to decrease the expression level of DDR1 in cells, and (vi) an activity to decrease the expression level of TGF-? in cells.
    Type: Application
    Filed: August 23, 2012
    Publication date: September 4, 2014
    Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Mei Ono, Yuji Sano, Tsukasa Suzuki
  • Publication number: 20140248283
    Abstract: The present invention provides and includes monoclonal antibodies (mAbs) preferentially selective for HER2 antigens, hybridoma lines that secrete these HER2 antibodies or antibody fragments, and the use of such antibodies and antibody fragments to detect HER2 antigens, particularly those expressed by cancer cells. The present invention also includes antibodies that are specific for or show preferential binding to a soluble or secreted form of HER2. The present invention also includes an antibody or antibody fragment that is capable of reducing the activity of HER2 in at least one form, including a soluble form or a secreted form. The present invention further includes chimeric antibodies, processes for producing monoclonal and chimeric antibodies or monoclonal or chimeric antibodies, and their therapeutic uses, particularly in the detection of cancer most preferentially in human breast, stomach, and colon.
    Type: Application
    Filed: May 13, 2014
    Publication date: September 4, 2014
    Applicant: ALPER BIOTECH, LLC
    Inventor: Özge Alper
  • Patent number: 8822196
    Abstract: The invention provides chimeric antigen receptors (CARs) comprising an antigen binding domain of a KDR-1121 or DC101 antibody, an extracellular hinge domain, a T cell receptor transmembrane domain, and an intracellular domain T cell receptor signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are also disclosed.
    Type: Grant
    Filed: May 2, 2013
    Date of Patent: September 2, 2014
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Steven A. Rosenberg, Dhanalakshmi Chinnasamy
  • Publication number: 20140235833
    Abstract: The present invention relates to an isolated antibody against HER1, an isolated antibody against CD147, an isolated antibody against CD73, and an isolated antibody against EpCAM; reagents and compositions including said antibodies; and uses of said reagents, compositions, and antibodies. The present invention also relates to nucleic acids and vectors expressing said antibodies. The invention further relates to transformants comprising said nucleic acids or vectors.
    Type: Application
    Filed: April 30, 2014
    Publication date: August 21, 2014
    Applicant: FUJITA HEALTH UNIVERSITY
    Inventors: Atsushi SUGIOKA, Gene KUROSAWA, Mariko SUMITOMO, Yoshikazu KUROSAWA
  • Patent number: 8808701
    Abstract: The present invention is directed to humanized antibodies which bind the human C5a receptor and their use as therapeutic and diagnostic agents. The present invention is further directed toward nucleic acid sequences which encode said humanized antibodies, and their expression in recombinant host cells. In particular, the present invention is directed towards humanized antibodies derived from murine antibody 7F3 which specifically binds to the human C5a receptor.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: August 19, 2014
    Assignee: G2 Inflammation Pty Ltd
    Inventors: Peter Whitfeld, David Zahra, Charles Reay Mackay
  • Publication number: 20140220040
    Abstract: Anti-LRP6 antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. These anti-LRP6 antibodies can be used to enhance Wnt activity and/or antagonize Dkk1 activity. Also described are methods of therapy using such antibodies and antigen-binding regions to bind modulate Wnt/LRP6 signaling to promote tissue homeostasis, regeneration and repair in diseases such as, but not limited to, bone disorders, such as osteoporosis, rheumatoid arthritis, and osteolytic lesions caused by osteoarthritis and multiple myeloma, gastrointestinal disease and wound healing.
    Type: Application
    Filed: April 17, 2014
    Publication date: August 7, 2014
    Applicant: ARCA BIOPHARMA, INC.
    Inventors: Arie Abo, Minke Binnerts
  • Publication number: 20140219919
    Abstract: The present disclosure provides proteins comprising antigen binding sites of antibodies that bind to interleukin-11 (IL-11) receptor alpha (IL-11R?) and uses thereof, e.g., in therapy.
    Type: Application
    Filed: February 6, 2014
    Publication date: August 7, 2014
    Applicant: CSL Limited
    Inventors: Kirsten EDWARDS, Matthew HARDY, Veronika RAYZMAN, Michael WILSON
  • Publication number: 20140212439
    Abstract: The present invention provides an antibody which recognizes an epitope recognized by an antibody produced by a hybridoma SH348-1 (FERM BP-10836) or a hybridoma SH357-1 (FERM BP-10837), an antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, an antibody obtained by humanizing the antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, a pharmaceutical agent comprising the antibody as an active ingredient, etc.
    Type: Application
    Filed: May 22, 2013
    Publication date: July 31, 2014
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Jun Hasegawa, Toshiaki Ohtsuka, Atsushi Urano, Junko Yamaguchi, Toshinori Agatsuma, Kaori Nakahara, Takeshi Takizawa